CM
ICPT

Crestline Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Crestline Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-31,248
Closed -$2.62M – 242
2018
Q2 		$2.62M Buy
+31,248
New +$2.29M 0.28% 104

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Crestline Management's ICPT Position: Q3 2018 in Review

Crestline Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2018, closing a stake of 31,248 shares — an estimated $2.62M sold.

Crestline Management first reported a position in ICPT in Q2 2018 and held it in 1 quarter. The position peaked at $2.62M in Q2 2018. 175 funds tracked by Wall St. Rank hold ICPT as of Q3 2018.

  • Crestline Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 31,248 Intercept Pharmaceuticals, Inc. shares in Q3 2018, an estimated $2.62M.
  • Crestline Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Crestline Management's Intercept Pharmaceuticals, Inc. position peaked at $2.62M in Q2 2018.
  • 175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.